Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure
Open Access
- 2 December 2016
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 389 (10081) , 1831-1840
Abstract
No abstract availableKeywords
This publication has 164 references indexed in Scilit:
- Aliskiren, ALTITUDE, and the Implications for ATMOSPHEREEuropean Journal of Heart Failure, 2012
- Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunctionAmerican Heart Journal, 2009
- Peripherally expressed neprilysin reduces brain amyloid burden: A novel approach for treating Alzheimer's diseaseJournal of Neuroscience Research, 2008
- Detection of Soluble Angiotensin-Converting Enzyme 2 in Heart FailureJACC, 2008
- Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin‐mediated angioedemaBritish Journal of Pharmacology, 2008
- Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: Results of the Optimal Trial in Myocardial Infarction with Angiotensin II antagonist losartan (optimaal) echocardiographic substudyAmerican Heart Journal, 2004
- Effects of ACE inhibition and bradykinin antagonism on cardiovascular changes in uremic ratsKidney International, 2000
- Attenuated renal excretory response to atrial natriuretic peptide in congestive heart failure in manInternational Journal of Cardiology, 1991
- Effects of Enalapril on Mortality in Severe Congestive Heart FailureNew England Journal of Medicine, 1987
- Prostaglandins in Severe Congestive Heart FailureNew England Journal of Medicine, 1984